Antifibrinolytic Drugs Market Report 2025

This antifibrinolytic drugs market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The antifibrinolytic drugs market size has grown strongly in recent years. It will grow from $16.82 billion in 2024 to $17.84 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the increasing prevalence of bleeding disorders, rising number of surgical procedures, increasing use in dental surgeries, higher incidence of cardiovascular diseases, and improving access to healthcare services.

The antifibrinolytic drugs market size is expected to see strong growth in the next few years. It will grow to $22.31 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to the increasing geriatric population, growing number of trauma cases, expansion of minimally invasive surgeries, rising incidence of postpartum hemorrhage, and increasing focus on patient safety. Major trends in the forecast period include a shift towards personalized medicine, growing adoption of telemedicine, development of biosimilar antifibrinolytics, rise in prophylactic use during surgeries, and integration of AI in trauma care.

The increasing incidence of road accidents is projected to drive the growth of the antifibrinolytic drugs market in the future. This rise in road accidents can be attributed to several factors, including the use of smartphones, speeding, driving under the influence, and poor vehicle maintenance. Antifibrinolytic drugs play a crucial role in managing bleeding among road accident victims by stabilizing blood clots, minimizing excessive bleeding, and enhancing survival rates, making them essential in trauma care to prevent significant blood loss. For example, in April 2024, a report from the National Highway Traffic Safety Administration (NHTSA), a US federal agency, revealed that distracted driving was responsible for 3,308 fatalities and approximately 289,310 injuries in 2022, with 621 of those deaths involving vulnerable road users. This data underscores a troubling increase in fatality rates. Therefore, the rising incidence of road accidents is fueling the growth of the antifibrinolytic drugs market.

An increasing number of surgical procedures is expected to propel the growth of the antifibrinolytic drugs market going forward. Surgical procedures are rising due to several reasons, including advancements in medical technology, an aging population, increased awareness, and cultural and social factors. Antifibrinolytic drugs help reduce bleeding during surgery by preventing the breakdown of blood clots, leading to improved hemostasis and potentially decreasing the need for blood transfusions. For instance, in September 2023, according to the Global Survey 2022 report released by the International Society of Aesthetic Plastic Surgery, a US-based professional body of aesthetic plastic surgeons, plastic surgery procedures saw an 11.2% overall increase in 2022, with over 14.9 million surgeries globally, including a 41.3% rise in aesthetic surgery over four years, and liposuction remained the most common surgical procedure in both 2022 and 2021. Therefore, the increasing number of surgical procedures is driving the growth of the antifibrinolytic drugs market.

Major companies in the antifibrinolytic drugs market are focusing on innovative solutions, such as a first-to-consumer approach, to offer more accessible treatments for women. This approach involves marketing these medications directly to patients rather than through traditional healthcare providers. For example, in May 2024, Maxwellia Ltd., a UK-based healthcare company, launched two new pharmacy brands, Evana Heavy Period Relief 500 mg tablets and Ultravana Period Pain Relief 250 mg gastro-resistant tablets. Evana helps reduce heavy menstrual bleeding by up to 60%, while Ultravana provides effective relief for period pain. Both are available over the counter in UK pharmacies. These products are significant in improving women's health by addressing common yet often overlooked menstrual issues and empowering women to manage their symptoms more effectively.

Major companies operating in the antifibrinolytic drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, DAIICHI SANKYO COMPANY LIMITED, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceuticals, Aurobindo Pharma Limited, Cipla Limited, Intas Pharmaceuticals, Lupin Limited, Zydus Lifesciences Ltd., Hetero Drugs Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd, Macleods Pharmaceuticals Pvt Ltd, Mankind pharma Ltd, Emcure Pharmaceuticals ltd, Bharat Serums & Vaccines Ltd, Systopic Laboratories Pvt Ltd, Ozone Pharmaceuticals Ltd, ACIC Pharmaceuticals, AmeriGen Life Sciences LLP, Life Sciences Advanced Technologies Inc., Vitruvias Therapeutics Inc.

North America was the largest region in the antifibrinolytic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antifibrinolytic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antifibrinolytic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antifibrinolytic drugs are medications designed to prevent the breakdown of blood clots by inhibiting enzymes such as plasmin, which are essential for controlling excessive bleeding. These drugs are used to treat or prevent bleeding in conditions such as hemophilia, heavy menstrual bleeding, and during surgeries where substantial blood loss is anticipated.

The primary indications for antifibrinolytic drugs include gynecology, hereditary angioedema, fibrinolytic response testing, surgeries, and other uses. In gynecology, which focuses on the female reproductive system, these drugs help manage bleeding issues associated with gynecological conditions or surgical procedures. Antifibrinolytic drugs can be administered through various routes, including injectable, oral, and topical methods. They are used by a range of end users, including hospitals and clinics, ambulatory surgical centers, and trauma centers.

The antifibrinolytic drugs market research report is one of a series of new reports that provides antifibrinolytic drugs market statistics, including antifibrinolytic drugs industry global market size, regional shares, competitors with a antifibrinolytic drugs market share, detailed antifibrinolytic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the antifibrinolytic drugs industry. This antifibrinolytic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antifibrinolytic drugs market consists of sales of tranexamic acid, aminocaproic acid, aprotinin, epsilon-aminocaproic acid, and desmopressin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.